Russian Journal of AllergyRussian Journal of AllergyРоссийский Аллергологический Журнал1810-88302686-682XPublishing House ABV Press1697410.36691/RJA16974ReviewsНаучные обзорыResearch ArticleImmunobiological therapy of psoriasis: current state of the problemИммунобиологическая терапия псориаза: современное состояние проблемыhttps://orcid.org/0000-0002-7933-35154320-1196ArsenyevaAntonina A.АрсеньеваАнтонина Александровна
Russian Federation

MD, Cand. Sci. (Medicine), Assistant Professor

канд. мед. наук, доцент

a.a.arseneva@samsmu.ruhttps://orcid.org/0000-0003-0941-98711313-9021MigachevaNatalia B.МигачеваНаталья Бегиевна
Russian Federation

MD, Dr. Sci. (Medicine), Assistant Professor

д-р мед. наук, доцент

n.b.migacheva@samsmu.ruhttps://orcid.org/0000-0002-5905-18956607-8990LyaminArtem V.ЛяминАртем Викторович
Russian Federation

MD, Dr. Sci. (Medicine), Assistant Professor

д-р мед. наук, доцент

a.v.lyamin@samsmu.ruhttps://orcid.org/0000-0003-4114-52332179-5831KurmaevDmitry P.КурмаевДмитрий Петрович
Russian Federation

Cand. Sci. (Medicine)

канд. мед. наук

geriatry@mail.ruSamara State Medical UniversityСамарский государственный медицинский университет17122024281220242145025193009202405112024Copyright ©; 2024, Pharmarus Print MediaCopyright ©; 2024, Фармарус Принт Медиа2024Pharmarus Print MediaФармарус Принт Медиаhttps://rusalljournal.ru/raj/article/view/16974

Psoriasis remains one of the most prominent dermatological diseases and is not limited only to skin manifestations, but often affects internal organs, is burdened by the presence of polymorbid pathology.

Over time, the processes of understanding the mechanisms, diagnosis and treatment of this disease are evolving, and approaches to patient management are being improved. Both external treatment methods and systemic therapy are widely used. Against the background of an actively growing range of drugs used to treat psoriasis, it is quite difficult to make an individual choice for each individual patient, therefore, the most important area of scientific research is to find starting points for personalized therapy selection.

The use of genetically engineered biological drugs to influence certain parts of the immunopathological process is the most advanced line of therapy for psoriasis today. By inhibiting the corresponding proinflammatory cytokines, cellular signaling can be altered and, thus, further pathways of the inflammatory process can be inhibited.

Псориаз остается одним из наиболее значимых дерматологических заболеваний и не ограничивается кожными проявлениями, но часто затрагивает внутренние органы, отягощается наличием полиморбидной патологии.

С течением времени происходит эволюция процессов понимания механизмов, вопросов диагностики и лечения этого заболевания, совершенствуются подходы к ведению пациентов. Широко применяются как наружные методы лечения, так и системная терапия. На фоне активно растущего спектра препаратов, применяемых для лечения псориаза, иногда сложно сделать индивидуальный выбор для каждого пациента. Поэтому важнейшим направлением научных исследований является поиск отправных точек для персонифицированного подбора терапии.

Использование генно-инженерных биологических препаратов для воздействия на определенные звенья иммунопатологического процесса – передовая линия терапии псориаза. Ингибируя соответствующие провоспалительные цитокины, можно изменить клеточную сигнализацию и таким образом блокировать дальнейшие пути реализации воспалительного процесса.

psoriasisimmunobiological therapycytokinepsoriatic arthritistumor necrosis factor αinterleukin 17interleukin 23interleukin 12/23Janus kinaseпсориазиммунобиологическая терапияцитокинпсориатический артритфактор некроза опухоли αинтерлейкин 17интерлейкин 23интерлейкин 12/23янус-киназаGhoreschi K, Balato A, Enerbäck C, Sabat R. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet. 2021;397(10275):754–766. doi: 10.1016/S0140-6736(21)00184-7Ghoreschi K., Balato A., Enerbäck C., Sabat R. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis // Lancet. 2021. Vol. 397, N 10275. P. 754–766. doi: 10.1016/S0140-6736(21)00184-7Raharja A, Mahil SK, Barker JN. Psoriasis: a brief overview. Clin Med (Lond). 2021;21(3):170–173. doi: 10.7861/clinmed.2021-0257Raharja A., Mahil S.K., Barker J.N. Psoriasis: a brief overview // Clin Med (Lond). 2021. Vol. 21, N 3. P. 170–173. doi: 10.7861/clinmed.2021-0257Parisi R, Iskandar IYK, Kontopantelis E, et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590. doi: 10.1136/bmj.m1590Parisi R., Iskandar I.Y.K., Kontopantelis E., et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study // BMJ. 2020. Vol. 369. P. m1590. doi: 10.1136/bmj.m1590Afonina IS, Van Nuffel E, Beyaert R. Immune responses and therapeutic options in psoriasis. Cell Mol Life Sci. 2021;78(6):2709–2727. doi: 10.1007/s00018-020-03726-1Afonina I.S., Van Nuffel E., Beyaert R. Immune responses and therapeutic options in psoriasis // Cell Mol Life Sci. 2021. Vol. 78, N 6. P. 2709–2727. doi: 10.1007/s00018-020-03726-1Liu S, He M, Jiang J, et al. Triggers for the onset and recurrence of psoriasis: a review and update. Cell Commun Signal. 2024;22(1):108. doi: 10.1186/s12964-023-01381-0Liu S., He M., Jiang J., et al. Triggers for the onset and recurrence of psoriasis: a review and update // Cell Commun Signal. 2024. Vol. 22, N 1. P. 108. doi: 10.1186/s12964-023-01381-0Liang X, Ou C, Zhuang J, et al. Interplay between skin microbiota dysbiosis and the host immune system in psoriasis: potential pathogenesis. Front Immunol. 2021;12:764384. doi: 10.3389/fimmu.2021.764384Liang X., Ou C., Zhuang J., et al. Interplay between skin microbiota dysbiosis and the host immune system in psoriasis: potential pathogenesis // Front Immunol. 2021. Vol. 12. P. 764384. doi: 10.3389/fimmu.2021.764384Vijaya Chandra SH, Srinivas R, Dawson TL Jr, Common JE. Cutaneous Malassezia: commensal, pathogen, or protector? Front Cell Infect Microbiol. 2021;10:614446. doi: 10.3389/fcimb.2020.614446Vijaya Chandra S.H., Srinivas R., Dawson T.L. Jr, Common J.E. Cutaneous Malassezia: commensal, pathogen, or protector? // Front Cell Infect Microbiol. 2021. Vol. 10. P. 614446. doi: 10.3389/fcimb.2020.614446Dascălu RC, Bărbulescu AL, Stoica LE, et al. Review: a contemporary, multifaced insight into psoriasis pathogenesis. J Pers Med. 2024;14(5):535. doi: 10.3390/jpm14050535Dascălu R.C., Bărbulescu A.L., Stoica L.E., et al. Review: a contemporary, multifaced insight into psoriasis pathogenesis // J Pers Med. 2024. Vol. 14, N 5. P. 535. doi: 10.3390/jpm14050535Arora K, Hazarika N, Kumari R, Chawla H. Quality of life in psoriasis: a cross-sectional study from North India. Indian J Dermatol. 2024;69(1):38–43. doi: 10.4103/ijd.ijd_144_23Arora K., Hazarika N., Kumari R., Chawla H. Quality of life in psoriasis: a cross-sectional study from North India // Indian J Dermatol. 2024. Vol. 69, N 1. P. 38–43. doi: 10.4103/ijd.ijd_144_23Tokuyama M, Mabuchi T. New treatment addressing the pathogenesis of psoriasis. Int J Mol Sci. 2020;21(20):7488. doi: 10.3390/ijms21207488Tokuyama M., Mabuchi T. New treatment addressing the pathogenesis of psoriasis // Int J Mol Sci. 2020. Vol. 21, N 20. P. 7488. doi: 10.3390/ijms21207488Azuaga AB, Ramírez J, Cañete JD. Psoriatic arthritis: pathogenesis and targeted therapies. Int J Mol Sci. 2023;24(5):4901. doi: 10.3390/ijms24054901Azuaga A.B., Ramírez J., Cañete J.D. Psoriatic arthritis: pathogenesis and targeted therapies // Int J Mol Sci. 2023. Vol. 24, N 5. P. 4901. doi: 10.3390/ijms24054901Buerger C. Epidermal mTORC1 signaling contributes to the pathogenesis of psoriasis and could serve as a therapeutic target. Front Immunol. 2018;9:2786. doi: 10.3389/fimmu.2018.02786Buerger C. Epidermal mTORC1 signaling contributes to the pathogenesis of psoriasis and could serve as a therapeutic target // Front Immunol. 2018. Vol. 9. P. 2786. doi: 10.3389/fimmu.2018.02786Boehncke WH. Systemic inflammation and cardiovascular comorbidity in psoriasis patients: causes and consequences. Front Immunol. 2018;9:579. doi: 10.3389/fimmu.2018.00579Boehncke W.H. Systemic inflammation and cardiovascular comorbidity in psoriasis patients: causes and consequences // Front Immunol. 2018. Vol. 9. P. 579. doi: 10.3389/fimmu.2018.00579Neurath L, Sticherling M, Schett G, Fagni F. Targeting cytokines in psoriatic arthritis. Cytokine Growth Factor Rev. 2024;78:1–13. doi: 10.1016/j.cytogfr.2024.06.001Neurath L., Sticherling M., Schett G., Fagni F. Targeting cytokines in psoriatic arthritis // Cytokine Growth Factor Rev. 2024. Vol. 78. P. 1–13. doi: 10.1016/j.cytogfr.2024.06.001Soomro M, Hum R, Barton A, Bowes J. Genetic studies investigating susceptibility to psoriatic arthritis: a narrative review. Clin Ther. 2023;45(9):810–815. doi: 10.1016/j.clinthera.2023.07.003Soomro M., Hum R., Barton A., Bowes J. Genetic studies investigating susceptibility to psoriatic arthritis: a narrative review // Clin Ther. 2023. Vol. 45, N 9. P. 810–815. doi: 10.1016/j.clinthera.2023.07.003Boix-Amorós A, Badri MH, Manasson J, et al. Alterations in the cutaneous microbiome of patients with psoriasis and psoriatic arthritis reveal similarities between non-lesional and lesional skin. Ann Rheum Dis. 2023;82(4):507–514. doi: 10.1136/ard-2022-223389Boix-Amorós A., Badri M.H., Manasson J., et al. Alterations in the cutaneous microbiome of patients with psoriasis and psoriatic arthritis reveal similarities between non-lesional and lesional skin // Ann Rheum Dis. 2023. Vol. 82, N 4. P. 507–514. doi: 10.1136/ard-2022-223389Celoria V, Rosset F, Pala V, et al. The skin microbiome and its role in psoriasis: a review. Psoriasis (Auckl). 2023;13:71–78. doi: 10.2147/PTT.S328439Celoria V., Rosset F., Pala V., et al. The skin microbiome and its role in psoriasis: a review // Psoriasis (Auckl). 2023. Vol. 13. P. 71–78. doi: 10.2147/PTT.S328439Lee HJ, Kim M. Challenges and future trends in the treatment of psoriasis. Int J Mol Sci. 2023;24(17):13313. doi: 10.3390/ijms241713313Lee H.J., Kim M. Challenges and future trends in the treatment of psoriasis // Int J Mol Sci. 2023. Vol. 24. N 17. P. 13313. doi: 10.3390/ijms241713313Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1475. doi: 10.3390/ijms20061475Rendon A., Schäkel K. Psoriasis pathogenesis and treatment // Int J Mol Sci. 2019. Vol. 20, N 6. P. 1475. doi: 10.3390/ijms20061475Zhukova OV, Kruglova LS, Sharapova EN. Combined ultraviolet therapy and methotrexate in treatment of patients with severe forms of psoriasis. Russian Journal of Clinical Dermatology and Venereology. 2015;14(2):66–73. (In Russ). doi: 10.17116/klinderma201514266-72Жукова О.В., Круглова Л.С., Шарапова Е.Н. Сочетанная ультрафиолетовая терапия и метотрексат в лечении больных тяжелыми формами псориаза // Клиническая дерматология и венерология. 2015. Т. 14, № 2. С. 66–73. doi: 10.17116/klinderma201514266-72Mohd Noor AA, Azlan M, Mohd Redzwan N. Orchestrated cytokines mediated by biologics in psoriasis and its mechanisms of action. Biomedicines. 2022;10(2):498. doi: 10.3390/biomedicines10020498Mohd Noor A.A., Azlan M., Mohd Redzwan N. Orchestrated cytokines mediated by biologics in psoriasis and its mechanisms of action // Biomedicines. 2022. Vol. 10, N 2. P. 498. doi: 10.3390/biomedicines10020498Hsieh CL, Yu SJ, Lai KL, et al. IFN-γ, IL-17A, IL-4, and IL-13: potential biomarkers for prediction of the effectiveness of biologics in psoriasis patients. Biomedicines. 2024;12(5):1115. doi: 10.3390/biomedicines12051115Hsieh C.L., Yu S.J., Lai K.L., et al. IFN-γ, IL-17A, IL-4, and IL-13: Potential biomarkers for prediction of the effectiveness of biologics in psoriasis patients // Biomedicines. 2024. Vol. 12, N 5. P. 1115. doi: 10.3390/biomedicines12051115Armstrong AW, Puig L, Joshi A, et al. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020;156(3):258–269. doi: 10.1001/jamadermatol.2019.4029Armstrong A.W., Puig L., Joshi A., et al. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis // JAMA Dermatol. 2020. Vol. 156, N 3. P. 258–269. doi: 10.1001/jamadermatol.2019.4029Kremenevski I, Sander O, Sticherling M, et al. Paradoxical reactions to biologicals in chronic inflammatory systemic diseases. Dtsch Arztebl Int. 2022;119(6):88–95. doi: 10.3238/arztebl.m2022.0067Kremenevski I., Sander O., Sticherling M., et al. Paradoxical reactions to biologicals in chronic inflammatory systemic diseases // Dtsch Arztebl Int. 2022. Vol. 119, N 6. P. 88–95. doi: 10.3238/arztebl.m2022.0067Scott LJ. Etanercept: a review of its use in autoimmune inflammatory diseases. Drugs. 2014;74(12):1379–1410. doi: 10.1007/s40265-014-0258-9Scott L.J. Etanercept: a review of its use in autoimmune inflammatory diseases // Drugs. 2014. Vol. 74, N 12. P. 1379–1410. doi: 10.1007/s40265-014-0258-9Rumyantseva OA, Bochkova AG, Urumova MM, et al. Clinical experience with etanercept in the treatment of patients with ankylosing spondylitis. Rheumatology Science and Practice. 2018;56(2):189–195. (In Russ). doi: 10.14412/1995-4484-2018-189-195Румянцева О.А., Бочкова А.Г., Урумова М.М., и др. Клинический опыт лечения этанерцептом больных анкилозирующим спондилитом // Научно-практическая ревматология. 2018. Т. 56, № 2. С. 189–195. doi: 10.14412/1995-4484-2018-189-195Pchelintseva AO, Panasyuk EYu, Ryabitseva OF, et al. Efficacy of etanercept in patients with rheumatoid arthritis (results of the Russian multicenter ETALON study). Rheumatology Science and Practice. 2013;51(6):639–645. (In Russ). doi: 10.14412/1995-4484-2013-639-45Пчелинцева А.О., Панасюк Е.Ю., Рябицева О.Ф., и др. Эффективность этанерцепта у больных ревматоидным артритом (результаты российского многоцентрового исследования ЭТАЛОН) // Научно-практическая ревматология. 2013. Т. 51, № 6. С. 639–645. doi: 10.14412/1995-4484-2013-639-45Karateev AE, Lila AM. New etanercept biosimilar — expanding treatment options for immune-mediated inflammatory rheumatic diseases. Modern Rheumatology Journal. 2022;16(6):92–97. (In Russ). doi: 10.14412/1996-7012-2022-6-92-97Каратеев А.Е., Лила А.М. Новый биосимиляр этанерцепта – расширение возможностей лечения иммуновоспалительных ревматических заболеваний // Современная ревматология. 2022. Т. 16, № 6. С. 92–97. doi: 10.14412/1996-7012-2022-6-92-97Mazurov VI, Lila AM, Korotaeva TV. Erelzi® – biosimilar of etanercept in the treatment of rheumatic diseases and psoriasis (Resolution of the Expert Panel). Modern Rheumatology Journal. 2021;15(4):129–131. (In Russ). doi: 10.14412/1996-7012-2021-4-129-131Мазуров В.И., Лила А.М., Коротаева Т.В. Эрелзи® – биоаналог этанерцепта в лечении ревматических заболеваний и псориаза (резолюция Совета экспертов) // Современная ревматология. 2021. Т. 15, № 4. С. 129–131. doi: 10.14412/1996-7012-2021-4-129-131Ruiz Garcia V, Burls A, Cabello JB, et al. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. Cochrane Database Syst Rev. 2017;9(9):CD007649. doi: 10.1002/14651858.CD007649.pub4Ruiz Garcia V., Burls A., Cabello J.B., et al. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults // Cochrane Database Syst Rev. 2017. Vol. 9, N 9. P. CD007649. doi: 10.1002/14651858.CD007649.pub4Esposito M, Carubbi F, Giunta A, et al. Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis. Expert Rev Clin Immunol. 2020;16(2):119–128. doi: 10.1080/1744666X.2020.1713754Esposito M., Carubbi F., Giunta A., et al. Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis // Expert Rev Clin Immunol. 2020. Vol. 16, N 2. P. 119–128. doi: 10.1080/1744666X.2020.1713754Padda IS, Bhatt R, Parmar M. Apremilast. [Updated 2023 Jul 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Available from: https://www.ncbi.nlm.nih.gov/books/NBK572078Padda I.S., Bhatt R., Parmar M. Apremilast. [Updated 2023 Jul 10] // StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Available from: https://www.ncbi.nlm.nih.gov/books/NBK572078Loginova EYu, Korsakova YuL, Koltakova AD, et al. The efficacy and safety of apremilast in patients with psoriatic arthritis concurrent with comorbidity in clinical practice. Rheumatology Science and Practice. 2019;57(3):299–306. (In Russ). doi: 10.14412/1995-4484-2019-299-306Логинова Е.Ю., Корсакова Ю.Л., Колтакова А.Д., и др. Эффективность и безопасность апремиласта у больных псориатическим артритом в сочетании с коморбидной патологией в клинической практике // Научно-практическая ревматология. 2019 Т. 57, № 3. С. 299–306. doi: 10.14412/1995-4484-2019-299-306Krueger JG, Wharton KA Jr, Schlitt T, et al. IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis. J Allergy Clin Immunol. 2019;144(3):750–763. doi: 10.1016/j.jaci.2019.04.029Krueger J.G., Wharton K.A. Jr, Schlitt T., et al. IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis // J Allergy Clin Immunol. 2019. Vol. 144, N 3. P. 750–763. doi: 10.1016/j.jaci.2019.04.029Iznardo H, Puig L. The safety of brodalumab for the treatment of psoriasis. Expert Opin Drug Saf. 2020;19(4):365–372. doi: 10.1080/14740338.2020.1730326Iznardo H., Puig L. The safety of brodalumab for the treatment of psoriasis // Expert Opin Drug Saf. 2020. Vol. 19, N 4. P. 365–372. doi: 10.1080/14740338.2020.1730326Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet. 2021;397(10273):475–486. doi: 10.1016/S0140-6736(21)00126-4Gordon K.B., Foley P., Krueger J.G., et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial // Lancet. 2021. Vol. 397, N 10273. P. 475–486. doi: 10.1016/S0140-6736(21)00126-4Korotaeva TV, Mazurov VI, Lila AM, et al. Netakimab for the treatment of psoriatic arthritis: 3-year results of the phase III BCD-085-8/PATERA study. Modern Rheumatology Journal. 2024;18(4):33–42. (In Russ). doi: 10.14412/1996-7012-2024-4-33-42Коротаева Т.В., Мазуров В.И., Лила А.М., и др. Нетакимаб для лечения псориатического артрита: результаты 3 лет исследования фазы III BCD085-8/PATERA // Современная ревматология. 2024. Т. 18, № 4. С. 33–42. doi: 10.14412/1996-7012-2024-4-33-42Dubinina TV, Gaydukova IZ, Sableva NА, et al. Comparative pharmacoeconomic effectiveness of interleukin-17 inhibitors for the treatment of ankylosing spondylitis. Rheumatology Science and Practice. 2022;60(6):594–601. (In Russ). doi: 10.47360/1995-4484-2022-594-601Дубинина Т.В., Гайдукова И.З., Саблева Н.А., и др. Сравнительная оценка клинико-экономической эффективности ингибиторов интерлейкина 17 при лечении анкилозирующего спондилита // Научно-практическая ревматология. 2022. Т. 60, № 6. С. 594–601. doi: 10.47360/1995-4484-2022-594-601Tarasenko GN, Patronov IV. Netakimab in the treatment of psoriatic erythroderma. Medical Council. 2024;(14):78–81. (In Russ). doi: 10.21518/ms2024-335Тарасенко Г.Н., Патронов И.В. Нетакимаб в терапии псориатической эритродермии // Медицинский совет. 2024. № 14. С. 78–81. doi: 10.21518/ms2024-335Kurdina MI, Kolenko NG. Therapy of netakimab in nail psoriasis. Medical Council. 2024;(2):144–152. (In Russ). doi: 10.21518/ms2024-054Курдина М.И., Коленько Н.Г. Терапия нетакимабом псориатической ониходистрофии // Медицинский совет. 2024. № 2. С. 144–152. doi: 10.21518/ms2024-054Svechnikova EV, Zhufina SE, Morzhanaeva MA. Clinical case: switching from basic therapy with methotrexate to therapy with netakimab, an IL-17 inhibitor, in a patient with severe psoriasis. Medical Council. 2023;(2):69–74. (In Russ). doi: 10.21518/ms2023-012Свечникова Е.В., Жуфина С.Е., Моржанаева М.А. Клинический случай: переход с базисной терапии метотрексатом на терапию ингибитором интерлейкина-17А нетакимабом у пациента с псориазом тяжелого течения // Медицинский Совет. 2023. № 2. С. 69–74. doi: 10.21518/ms2023-012Yang K, Oak ASW, Elewski BE. Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review. Am J Clin Dermatol. 2021;22(2):173–192. doi: 10.1007/s40257-020-00578-0Yang K., Oak A.S.W., Elewski B.E. Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review // Am J Clin Dermatol. 2021. Vol. 22, N 2. P. 173–192. doi: 10.1007/s40257-020-00578-0Banaszczyk K. Tildrakizumab in the treatment of psoriasis – literature review. Reumatologia. 2019;57(4):234–238. doi: 10.5114/reum.2019.87620Banaszczyk K. Tildrakizumab in the treatment of psoriasis – literature review // Reumatologia. 2019. Vol. 57, N 4. P. 234–238. doi: 10.5114/reum.2019.87620Papp K, Warren RB, Green L, et al. Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study. Lancet Rheumatol. 2023;5(9):e542–e552. doi: 10.1016/S2665-9913(23)00120-0Papp K., Warren R.B., Green L., et al. Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study // Lancet Rheumatol. 2023. Vol. 5, N 9. P. e542–e552. doi: 10.1016/S2665-9913(23)00120-0Shafieva IA, Bulgakova SV, Kurmaev DP, Treneva EV. Use of tofacitinib in psoriatic arthritis (literature review). Medical Council. 2024;18(12):114–122. (In Russ). doi: 10.21518/ms2024-230Шафиева И.А., Булгакова С.В., Курмаев Д.П., Тренева Е.В. Применение тофацитиниба при псориатическом артрите (обзор литературы) // Медицинский совет. 2024. № 12. С. 114–122. doi: 10.21518/ms2024-230Chandran V, Malkov VA, Ito KL, et al. Pharmacodynamic effects of filgotinib treatment driving clinical improvement in patients with active psoriatic arthritis enrolled in the EQUATOR trial. RMD Open. 2023;9(4):e003550. doi: 10.1136/rmdopen-2023-003550Chandran V., Malkov V.A., Ito K.L., et al. Pharmacodynamic effects of filgotinib treatment driving clinical improvement in patients with active psoriatic arthritis enrolled in the EQUATOR trial // RMD Open. 2023. Vol. 9, N 4. P. e003550. doi: 10.1136/rmdopen-2023-003550Zhang J, Qi F, Dong J, et al. Application of baricitinib in dermatology. J Inflamm Res. 2022;15:1935–1941. doi: 10.2147/JIR.S356316Zhang J., Qi F., Dong J., et al. Application of baricitinib in dermatology // J Inflamm Res. 2022. Vol. 15. P. 1935–1941. doi: 10.2147/JIR.S356316Ciechanowicz P, Rakowska A, Sikora M, Rudnicka L. JAK-inhibitors in dermatology: current evidence and future applications. J Dermatolog Treat. 2019;30(7):648–658. doi: 10.1080/09546634.2018.1546043Ciechanowicz P., Rakowska A., Sikora M., Rudnicka L. JAK-inhibitors in dermatology: current evidence and future applications // J Dermatolog Treat. 2019. Vol. 30, N 7. P. 648–658. doi: 10.1080/09546634.2018.1546043Mease P, Helliwell P, Silwinska-Stanczyk P, et al. Efficacy and safety of the TYK2/JAK1 inhibitor brepocitinib for active psoriatic arthritis: a phase IIb randomized controlled trial. Arthritis Rheumatol. 2023;75(8):1370–1380. doi: 10.1002/art.42519Mease P., Helliwell P., Silwinska-Stanczyk P., et al. Efficacy and safety of the TYK2/JAK1 inhibitor brepocitinib for active psoriatic arthritis: a phase IIb randomized controlled trial // Arthritis Rheumatol. 2023. Vol. 75, N 8. P. 1370–1380. doi: 10.1002/art.42519Strober B, Thaçi D, Sofen H, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 program for evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol. 2023;88(1):40–51. doi: 10.1016/j.jaad.2022.08.061Strober B., Thaçi D., Sofen H., et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 program for evaluation of TYK2 inhibitor psoriasis second trial // J Am Acad Dermatol. 2023. Vol. 88, N 1. P. 40–51. doi: 10.1016/j.jaad.2022.08.061Imura C, Ueyama A, Sasaki Y, et al. A novel RORγt inhibitor is a potential therapeutic agent for the topical treatment of psoriasis with low risk of thymic aberrations. J Dermatol Sci. 2019;93(3):176–185. doi: 10.1016/j.jdermsci.2019.03.002Imura C., Ueyama A., Sasaki Y., et al. A novel RORγt inhibitor is a potential therapeutic agent for the topical treatment of psoriasis with low risk of thymic aberrations // J Dermatol Sci. 2019. Vol. 93, N 3. P. 176–185. doi: 10.1016/j.jdermsci.2019.03.002Berstein G, Zhang Y, Berger Z, et al. A phase I, randomized, double-blind study to assess the safety, tolerability and efficacy of the topical RORC2 inverse agonist PF-06763809 in participants with mild-to-moderate plaque psoriasis. Clin Exp Dermatol. 2021;46(1):122–129. doi: 10.1111/ced.14412Berstein G., Zhang Y., Berger Z., et al. A phase I, randomized, double-blind study to assess the safety, tolerability and efficacy of the topical RORC2 inverse agonist PF-06763809 in participants with mild-to-moderate plaque psoriasis // Clin Exp Dermatol. 2021. Vol. 46, N 1. P. 122–129. doi: 10.1111/ced.14412Mohamed MF, Qian Y, D’Cunha R, et al. Pharmacokinetics, safety, and tolerability of cedirogant in healthy Japanese and Chinese adults. Clin Pharmacol Drug Dev. 2024;13(7):801–809. doi: 10.1002/cpdd.1386Mohamed M.F., Qian Y., D’Cunha R., et al. Pharmacokinetics, safety, and tolerability of cedirogant in healthy Japanese and Chinese adults // Clin Pharmacol Drug Dev. 2024. Vol. 13, N 7. P. 801–809. doi: 10.1002/cpdd.1386Tyring S, Moore A, Morita A, et al. Cedirogant in adults with psoriasis: a phase II, randomized, placebo-controlled clinical trial. Clin Exp Dermatol. 2024;49(11):1347–1355. doi: 10.1093/ced/llae152Tyring S., Moore A., Morita A., et al. Cedirogant in adults with psoriasis: a phase II, randomized, placebo-controlled clinical trial // Clin Exp Dermatol. 2024. Vol. 49, N 11. P. 1347–1355. doi: 10.1093/ced/llae152Zanin-Zhorov A, Weiss JM, Trzeciak A, et al. Cutting edge: selective oral ROCK2 inhibitor reduces clinical scores in patients with psoriasis vulgaris and normalizes skin pathology via concurrent regulation of IL-17 and IL-10. J Immunol. 2017;198(10):3809–3814. doi: 10.4049/jimmunol.1602142Zanin-Zhorov A., Weiss J.M., Trzeciak A., et al. Cutting edge: selective oral ROCK2 inhibitor reduces clinical scores in patients with psoriasis vulgaris and normalizes skin pathology via concurrent regulation of IL-17 and IL-10 // J Immunol. 2017. Vol. 198, N 10. P. 3809–3814. doi: 10.4049/jimmunol.1602142Yoon JH, Nguyen TT, Duong VA, et al. Determination of KD025 (SLx-2119), a selective ROCK2 inhibitor, in rat plasma by high-performance liquid chromatography-tandem mass spectrometry and its pharmacokinetic application. Molecules. 2020;25(6):1369. doi: 10.3390/molecules25061369Yoon J.H., Nguyen T.T., Duong V.A., et al. Determination of KD025 (SLx-2119), a selective ROCK2 inhibitor, in rat plasma by high-performance liquid chromatography-tandem mass spectrometry and its pharmacokinetic application // Molecules. 2020. Vol. 25, N 6. P. 1369. doi: 10.3390/molecules25061369Ali F, Ilyas A. Belumosudil with ROCK-2 inhibition: chemical and therapeutic development to FDA approval for the treatment of chronic graft-versus-host disease. Curr Res Transl Med. 2022;70(3):103343. doi: 10.1016/j.retram.2022.103343Ali F., Ilyas A. Belumosudil with ROCK-2 inhibition: chemical and therapeutic development to FDA approval for the treatment of chronic graft-versus-host disease // Curr Res Transl Med. 2022. Vol. 70, N 3. P. 103343. doi: 10.1016/j.retram.2022.103343Huang Y, Mao CR, Lou Y, et al. Design, synthesis, and biological evaluation of an orally bioavailable, potent, and selective ROCK2 inhibitor for psoriasis treatment. J Med Chem. 2023;66(22):15205–15229. doi: 10.1021/acs.jmedchem.3c01297Huang Y., Mao C.R., Lou Y., et al. Design, synthesis, and biological evaluation of an orally bioavailable, potent, and selective ROCK2 inhibitor for psoriasis treatment // J Med Chem. 2023. Vol. 66, N 22. P. 15205–15229. doi: 10.1021/acs.jmedchem.3c01297Schett G, Rahman P, Ritchlin C, et al. Psoriatic arthritis from a mechanistic perspective. Nat Rev Rheumatol. 2022;18(6):311–325. doi: 10.1038/s41584-022-00776-6Schett G., Rahman P., Ritchlin C., et al. Psoriatic arthritis from a mechanistic perspective // Nat Rev Rheumatol. 2022. Vol. 18, N 6. P. 311–325. doi: 10.1038/s41584-022-00776-6Lee BW, Moon SJ. Inflammatory cytokines in psoriatic arthritis: understanding pathogenesis and implications for treatment. Int J Mol Sci. 2023;24(14):11662. doi: 10.3390/ijms241411662Lee B.W., Moon S.J. Inflammatory cytokines in psoriatic arthritis: understanding pathogenesis and implications for treatment // Int J Mol Sci. 2023. Vol. 24, N 14. P. 11662. doi: 10.3390/ijms241411662Bellinato F, Maurelli M, Geat D, et al. Managing the patient with psoriasis and metabolic comorbidities. Am J Clin Dermatol. 2024;25(4):527–540. doi: 10.1007/s40257-024-00857-0Bellinato F., Maurelli M., Geat D., et al. Managing the patient with psoriasis and metabolic comorbidities // Am J Clin Dermatol. 2024. Vol. 25, N 4. P. 527–540. doi: 10.1007/s40257-024-00857-0Nast A, Smith C, Spuls PI, et al. EuroGuiDerm Guideline on the systemic treatment of psoriasis vulgaris – Part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020;34(11):2461–2498. doi: 10.1111/jdv.16915Nast A., Smith C., Spuls P.I., et al. EuroGuiDerm Guideline on the systemic treatment of psoriasis vulgaris – Part 1: treatment and monitoring recommendations // J Eur Acad Dermatol Venereol. 2020. Vol. 34, N 11. P. 2461–2498. doi: 10.1111/jdv.16915Reid C, Griffiths CEM. Psoriasis and treatment: past, present and future aspects. Acta Derm Venereol. 2020;100(3):adv00032. doi: 10.2340/00015555-3386Reid C., Griffiths C.E.M. Psoriasis and treatment: past, present and future aspects // Acta Derm Venereol. 2020. Vol. 100, N 3. P. adv00032. doi: 10.2340/00015555-3386